BC
PRTK

Broadfin Capital’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Broadfin Capital’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-477,607
Closed -$6.21M – 59
2018
Q1 		$6.21M Buy
477,607
+71,400
+18% +$1.06M 0.97% 32
2017
Q4 		$7.27M Hold
406,207
– – 1.19% 23
2017
Q3 		$10.2M Buy
406,207
+129,187
+47% +$3.01M 1.51% 20
2017
Q2 		$6.68M Buy
277,020
+53,158
+24% +$1.18M 0.81% 32
2017
Q1 		$4.31M Sell
223,862
-562,272
-72% -$8.86M 0.52% 38
2016
Q4 		$12.1M Hold
786,134
– – 1.34% 23
2016
Q3 		$10.2M Sell
786,134
-17,198
-2% -$228K 0.92% 33
2016
Q2 		$11.2M Buy
803,332
+273,050
+51% +$4.02M 1.09% 26
2016
Q1 		$8.04M Sell
530,282
-1
-0% -$15 0.78% 34
2015
Q4 		$10.1M Hold
530,283
– – 0.62% 44
2015
Q3 		$10.1M Hold
530,283
– – 0.56% 47
2015
Q2 		$13.7M Buy
530,283
+270,000
+104% +$7.66M 0.73% 40
2015
Q1 		$8.14M Hold
260,283
– – 0.63% 45
2014
Q4 		$8.03M Buy
+260,283
New +$6.21M 0.7% 39

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
APCM
Arbiter Partners Capital Management New York $190M AUM 50.42% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Broadfin Capital's PRTK Position: Q2 2018 in Review

Broadfin Capital sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2018, closing a stake of 477,607 shares — an estimated $6.21M sold.

Broadfin Capital first reported a position in PRTK in Q4 2014 and held it in 14 quarters. The position peaked at $13.7M in Q2 2015. 110 funds tracked by Wall St. Rank hold PRTK as of Q2 2018.

  • Broadfin Capital reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
  • Broadfin Capital sold 477,607 Paratek Pharmaceuticals, Inc. shares in Q2 2018, an estimated $6.21M.
  • Broadfin Capital first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2014 and held it in 14 quarters.
  • Broadfin Capital's Paratek Pharmaceuticals, Inc. position peaked at $13.7M in Q2 2015.
  • 110 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2018.

Based on Broadfin Capital's 13F filing for Q2 2018, filed 14 Aug 2018.